ImmunoProfile

ImmunoProfile is a biotechnology startup founded in 2018 in the United States. The company's slogan, "ImmunoProfile® is Antibody Status, Made Simple," encapsulates its innovative technology aimed at revolutionizing infectious disease vulnerability assessment. ImmunoProfile has developed a unique testing kit that enables individuals to determine their antibody status to a range of infectious diseases through a simple finger prick, eliminating the need for blood draw at a medical facility. This technology has broad applications across various sectors, including families, employers, military, nursing and healthcare professional students, senior centers, and individuals seeking immunization compliance and titer requirements. The potential of ImmunoProfile's solution to transform risk assessment and ensure protection is substantial.

ImmunoProfile secured a significant $500.00K Venture Round investment on 06 July 2023, highlighting investor confidence in its groundbreaking technology and the potential impact it promises to deliver. The absence of specific investor details indicates a potential opportunity for collaboration with venture capital firms, corporate investors, or other entities interested in pioneering developments in biotechnology and healthcare. As the company continues to grow, its commitment to simplifying antibody testing and contributing to public health underscores its positioning as a promising investment opportunity in the biotechnology sector.